Lurasidone for schizophrenia: A brief review of a new second-generation antipsychotic

Clinical Schizophrenia and Related Psychoses

Volumn 4, Issue 4, 2011, Pages 251-257

  Citrome, Leslie ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Efficacy; Lurasidone; Schizophrenia; Tolerability

Indexed keywords

ASENAPINE; DILTIAZEM; DOPAMINE 2 RECEPTOR; HALOPERIDOL; KETOCONAZOLE; LURASIDONE; OLANZAPINE; PLACEBO; RIFAMPICIN; RISPERIDONE; ZIPRASIDONE;

AGITATION; AKATHISIA; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; HUMAN; LIVER METABOLISM; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; QT INTERVAL; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

AKATHISIA, DRUG-INDUCED; ANIMALS; ANTIPSYCHOTIC AGENTS; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOINDOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; THIAZOLES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WEIGHT GAIN;

EID: 78650664657     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.4.4.5     Document Type: Review

References (27)

1. United States Food and Drug Administration. FDA approves Latuda to treat schizophrenia in adults. Press release, 28 October 2010. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm (accessed 28 October 2010).
2. Citrome L. Lurasidone for schizophrenia: A review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2010 Dec 3. doi: 10.1111/j.1742-1241.2010.02587.x. Epub ahead of print.
3. Citrome L. Iloperidone for schizophrenia: A review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009;63(8):1237-1248.
4. Citrome L. Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63(12):1762-1784.
5. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: Heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10(12):1917-1928.
6. Sunovion. Latuda (lurasidone HCl) Tablets Prescribing Information. http://www.latuda.com/LatudaPrescribingInformation.pdf (accessed 28 October 2010).
7. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: Rationale and perspectives. Curr Opin Investig Drugs 2010;11(7):802-812.
8. Ballaz SJ, Akil H, Watson SJ. The 5-HT7 receptor: Role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience 2007;149(1):192-202.
9. Shayegan DK, Stahl SM. Atypical antipsychotics: Matching receptor profile to individual patient's clinical profile. CNS Spectr 2004;9(Suppl 11):6-14.
10. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28(3):519-526.
11. Meyer JM, Loebel AD, Schweizer E. Lurasidone: A new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18(11):1715-1726.
12. Chiu YY, Preskorn S, Sarubbi D, Cucchiaro J, Loebel A. Effect of food on lurasidone absorption. Poster presented at the NCDEU Meeting, Boca Raton, Florida, 14-17 June 2010.
13. Citrome L. Using ziprasidone effectively: The food effect and dose-response. Adv Ther 2009;26(8):739-748.
14. Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: A randomized, open-label, crossover trial. J Clin Psychiatry 2009;70(1):58-62.
15. Loebel A, Cucchiaro J, Ogasa M, Silva R, Pikalov AA, Hsu J, et al. Efficacy of lurasidone: Summary of results from the clinical development program. Poster presented at the NCDEU Meeting, Boca Raton, Florida, 14-17 June 2010.
16. Dainippon Sumitomo Pharma America, Inc. Lurasidone HCL-A 6-Week Phase 3 Study of Patients with Acute Schizophrenia. (PEARL 3). Registry record. Available at: Http://clinicaltrials.gov/ct2/show/NCT00790192 (accessed 1 November 2010).
17. Loebel A, Cucchiaro J, Silva R, Ogasa M, Severs J, Marder SR. Efficacy of lurasidone in schizophrenia: Results of a pooled analysis based on a 5-factor model of schizophrenia. Abstract. Schizophr Res 2010;117(2-3):267.
18. Cucchiaro J, Potkin SG, Ogasa M, Loebel A. A double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Abstract. Schizophr Bull 2009;35(Suppl 1):342-343.
19. Harvey PD, Murasaki M, Cucchiaro J, Ogasa M, Loebel A. A three arm dose finding study of lurasidone: Efficacy and tolerability data. Abstract. Schizophr Res 2010;117(2-3):374-375.
20. Citrome L. Quantifying risk: The role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009;4(3):229-237.
21. Ereshefsky L, Jhee S, Phillips D, Peterson M, Ogasa M, Gertsik L, et al. Assessment of the Maximum Tolerated Dose (MTD) of lurasidone in patients with schizophrenia. Abstract. Schizophr Res 2010;117(2-3):381-382.
22. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, et al. Lurasidone in the treatment of acute schizophrenia: A double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(6):829-836.
23. Cucchiaro J, Silva R, Ogasa M, Xu J, Phillips D, Simonelli D, et al. Lurasidone in the treatment of acute schizophrenia: Results of the double-blind, placebo-controlled PEARL 2 trial. Abstract. Schizophr Res 2010;117(2-3):493.
24. Preskorn S, Chiu YY, Sarubbi D, Ogasa M, Cucchiaro J, Loebel A. Lurasidone pharmacokinetics: Assessment of potential drug-drug interactions. Poster presented at the NCDEU Meeting, Boca Raton, Florida, 14-17 June 2010.
25. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: A review of the clinical trials. CNS Drug Rev 2007;13(2):137-177.
26. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat 2006;2(4):427-443. (Pubitemid 46321873)
27. FDA. Drug Approval Package. Latuda (lurasidone hydrochloride) Tablets. 3 December 2010. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/ 200603Orig1s000TOC.cfm (accessed 16 December 2010).